Kymera Therapeutics
IPORevolutionary Medicines Catalyzed by Protein Degradation
Public · Boston, United States · Founded 2016 · $167.0M raised
- Headquarters
- Boston, Massachusetts
- Employees
- 51–200
- Founded
- 2016
- Business Model
- Other
- Website
- kymeratx.com
- Total Funding
- $167.0M
- Last Round
- $102.0M Series CMar 2020
- Rounds
- 2
- Type
- Public
About
Kymera Therapeutics is a clinical-stage biotechnology company pioneering targeted protein degradation to develop oral small molecule medicines addressing critical health problems in immunology and oncology. Its proprietary platform enables degradation of disease-causing proteins, transforming treatment paradigms for undruggable targets.
Summary
Kymera Therapeutics is a Biotech company based in Boston, United States, founded in 2016. It has raised $167.0M in total across 2 rounds, most recently a $102.0M Series C round in Mar 2020. Investors include Biotechnology Value Fund, Redmile Group and Bain Capital.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Dec 2025
Sign up to see all 5 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...